Breaking News Instant updates and real-time market news.

INTC

Intel

$48.30

-0.15 (-0.31%)

14:25
08/14/18
08/14
14:25
08/14/18
14:25

Intel discloses three security vulnerabilities reported by The Register

Intel has released the white paper on the three security vulnerabilities reported today by The Register. "Malicious applications may be able to infer the values of data in the operating system memory, or data from other applications," Intel said in the report. It explained, "When a program attempts to access data in memory, the logical memory address is translated to a physical address by the hardware. Accessing a logical or linear address that is not mapped to a physical location on the hardware will result in a terminal fault. Once the fault is triggered, there is a gap before resolution where the processor will use speculative execution to try to load data. During this time, the processor could speculatively access the level 1 data cache (L1D), potentially allowing side-channel methods to infer information that would otherwise be protected." Shares of Intel are down 1% to $47.94 in afternoon trading. Reference Link

  • 14

    Aug

  • 16

    Aug

  • 28

    Aug

  • 12

    Sep

INTC Intel
$48.30

-0.15 (-0.31%)

08/10/18
GSCO
08/10/18
DOWNGRADE
GSCO
Sell
Intel downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Toshiya Hari downgraded Intel (INTC) to Sell from Neutral and lowered his price target for the shares to $44 from $49. The chipmaker closed yesterday up 18c to $50.14. Hari coupled the downgrade with an upgrade of AMD (AMD) to Neutral from Sell. Intel's struggles with 10nm process technology makes the analyst incrementally more negative on the company's competitive positioning and margin outlook. He expects a worsening product mix in the near-term, ramp in 10nm costs and growing depreciation to drive margin pressure and Intel's earnings below consensus expectations. Hari sees downside risk in the shares.
08/10/18
08/10/18
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Intel (INTC) downgraded to Sell from Neutral at Goldman Sachs with analyst Toshiya Hari saying Intel's struggles with 10nm process technology makes the analyst incrementally more negative on the company's competitive positioning and margin outlook. 2. Booking Holdings (BKNG) downgraded to Neutral from Buy at Citi and UBS as well as Neutral from Overweight at JPMorgan. 3. Sysco (SYY) downgraded to Sell from Hold at Pivotal Research with analyst Ajay Jain saying he believes the move up in the stock over the past three months is inconsistent with growing industry headwinds as well as Sysco's company-specific issues. 4. Campbell Soup (CPB) downgraded to Underweight from Neutral at JPMorgan with analyst Ken Goldman saying he agrees with activist Third Point that Campbell's best option is to sell the company; however, he sees a sale as an unlikely outcome. 5. Redfin (RDFN) downgraded to Neutral from Buy at DA Davidson with analyst Tom White citing its Q2 results and below-consensus Q3 guidance. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
08/10/18
08/10/18
NO CHANGE

Fly Intel: Today's top analyst calls on Wall Street
Check out today's top analyst calls from around Wall Street, compiled by The Fly. GOLDMAN CUTS INTEL, UPGRADES AMD: Goldman Sachs analyst Toshiya Hari downgraded Intel (INTC) to Sell from Neutral and lowered his price target for the shares to $44 from $49. Hari coupled the downgrade with an upgrade of AMD (AMD) to Neutral from Sell. Intel's struggles with 10nm process technology made the analyst incrementally more negative on the company's competitive positioning and margin outlook. He expects a worsening product mix in the near-term, ramp in 10nm costs and growing depreciation to drive margin pressure and Intel's earnings below consensus expectations. The delay in Intel's new products will allow AMD to gain share in not only client computer processing units, and also in the "lucrative" server CPU market, Hari contended. He believes this makes for a balanced risk/reward profile on AMD shares. In late morning trading, Intel is down 2.5% and AMD is up fractionally. BOOKING HOLDINGS DOWNGRADED AT MULTIPLE FIRMS: UBS analyst Eric Sheridan downgraded Booking Holdings (BKNG) to Neutral from Buy and lowered his price target for the shares to $2,060 from $2,320 following the company's Q2 results. JPMorgan analyst Doug Anmuth downgraded Booking Holdings to Neutral from Overweight and lowered his price target for the shares to $2,070 from $2,385. Additionally, Citi analyst Mark May downgraded Booking Holdings to Neutral from Buy and lowered his price target for the shares to $2,150 from $2,350. Booking Holding is down over 2% in late morning trading. JPMORGAN CUTS CAMPBELL SOUP TO UNDERWEIGHT: JPMorgan analyst Ken Goldman downgraded Campbell Soup (CPB) to Underweight from Neutral with a $36 price target, saying he believes a sale of the company at a significant premium is unlikely. Campbell Soup is down over 2% in late morning trading. CANTOR SEES MANY REASONS FOR UNITEDHEALTH ACQUIRING ATHENAHEALTH: Numerous media sources cited a Dealreporter story indicating that UnitedHealth (UNH) is now in the second round of bidding for Athenahealth (ATHN), Cantor Fitzgerald analyst Steven Halper said in a research note. There are "many reasons" why UnitedHealth's Optum would benefit from the acquisition of Athenahealth, the analyst contended. With or without the deal, the analyst expects UnitedHealth will deploy capital and grow its various Optum businesses over time. He reiterated an Overweight rating on shares with a $300 price target.
08/14/18
JPMS
08/14/18
DOWNGRADE
Target $21
JPMS
Underweight
Macom downgraded to Underweight with $21 price target at JPMorgan
JPMorgan analyst Harlan Sur downgraded Macom Technology Solutions (MTSI) to Underweight with an unchanged price target of $21. With the stock above his price target, the analyst believes the market is already discounting "strong forward earnings power." The analyst also see the potential for margin pressures on current generation discrete Macom-based white box transceiver reference designs for 100G CWDM4 modules amid competition from Intel (INTC), Applied Optoelectronics (AAOI), and InnoLight.

TODAY'S FREE FLY STORIES

NBIX

Neurocrine

$85.72

-0.14 (-0.16%)

07:25
12/12/18
12/12
07:25
12/12/18
07:25
Hot Stocks
Breaking Hot Stocks news story on Neurocrine »

Neurocrine trading…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TSLA

Tesla

07:25
12/12/18
12/12
07:25
12/12/18
07:25
Recommendations
Tesla analyst commentary  »

Tesla poised to exceed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

LULU

Lululemon

$116.67

1.66 (1.44%)

07:25
12/12/18
12/12
07:25
12/12/18
07:25
Upgrade
Lululemon rating change  »

Citi upgrades Lululemon…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

UAA

Under Armour

$22.14

-0.25 (-1.12%)

07:25
12/12/18
12/12
07:25
12/12/18
07:25
Conference/Events
Under Armour to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 14

    Dec

AIMT

Aimmune

$23.25

0.18 (0.78%)

07:25
12/12/18
12/12
07:25
12/12/18
07:25
Conference/Events
Aimmune to host analyst day »

Analyst Day to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

UA

Under Armour

$20.87

-0.15 (-0.71%)

07:25
12/12/18
12/12
07:25
12/12/18
07:25
Conference/Events
Under Armour to host investor day »

Investor Day to be held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

  • 03

    Mar

EBAY

eBay

$29.05

0.07 (0.24%)

07:24
12/12/18
12/12
07:24
12/12/18
07:24
Downgrade
eBay rating change  »

Morgan Stanley admits to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

AAPL

Apple

$168.66

-0.95 (-0.56%)

07:20
12/12/18
12/12
07:20
12/12/18
07:20
Periodicals
Apple mulls shifting iPhone production if tariffs hit 25%, Bloomberg reports »

Apple suppliers will mull…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SHPG

Shire

$169.68

-0.44 (-0.26%)

, TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

07:20
12/12/18
12/12
07:20
12/12/18
07:20
Downgrade
Shire, Takeda Pharmaceutical rating change  »

Shire downgraded to Hold…

SHPG

Shire

$169.68

-0.44 (-0.26%)

TKPYY

Takeda Pharmaceutical

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 21

    Dec

  • 11

    Jan

07:20
12/12/18
12/12
07:20
12/12/18
07:20
General news
FX Update: The dollar has been trading mixed-to-firmer »

FX Update: The dollar has…

07:17
12/12/18
12/12
07:17
12/12/18
07:17
General news
Futures higher following release of Huawei CFO »

Stock futures are…

CORT

Corcept Therapeutics

$17.16

4.18 (32.20%)

07:17
12/12/18
12/12
07:17
12/12/18
07:17
Upgrade
Corcept Therapeutics rating change  »

Cantor upgrades Corcept…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DCO

Ducommun

$38.00

0.2 (0.53%)

07:13
12/12/18
12/12
07:13
12/12/18
07:13
Initiation
Ducommun initiated  »

Ducommun initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HSDT

Helius Medical

$9.94

-0.33 (-3.21%)

07:12
12/12/18
12/12
07:12
12/12/18
07:12
Hot Stocks
Helius Medical announces PoNS application for CE Mark »

Helius Medical announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ITCI

Intra-Cellular

$15.50

0.16 (1.04%)

07:12
12/12/18
12/12
07:12
12/12/18
07:12
Recommendations
Intra-Cellular analyst commentary  »

Intra-Cellular's NDA…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Sep

MNGPY

Man Group

$0.00

(0.00%)

07:11
12/12/18
12/12
07:11
12/12/18
07:11
Downgrade
Man Group rating change  »

Man Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ONCY

Oncolytics

$2.03

0.01 (0.50%)

, BMY

Bristol-Myers

$52.44

-0.15 (-0.29%)

07:10
12/12/18
12/12
07:10
12/12/18
07:10
Hot Stocks
Oncolytics treats first patient in pelareorep, carfilzomib with Opdivo trial »

Oncolytics (ONCY)…

ONCY

Oncolytics

$2.03

0.01 (0.50%)

BMY

Bristol-Myers

$52.44

-0.15 (-0.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

  • 29

    Dec

  • 24

    Jan

  • 20

    May

UNIT

Uniti Group

$19.59

0.52 (2.73%)

07:10
12/12/18
12/12
07:10
12/12/18
07:10
Downgrade
Uniti Group rating change  »

Uniti Group downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LII

Lennox

$207.29

-0.545 (-0.26%)

07:09
12/12/18
12/12
07:09
12/12/18
07:09
Hot Stocks
Lennox sees $347M in insurance proceeds for 2018, 2019 »

Overall for 2018 and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Dec

SRNE

Sorrento Therapeutics

$2.66

-0.27 (-9.22%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Recommendations
Sorrento Therapeutics analyst commentary  »

Sorrento Therapeutics has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDR

McDermott

$7.28

-0.37 (-4.84%)

, GE

General Electric

$6.77

-0.15 (-2.17%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
McDermott, Baker Hughes, selected for Equus Gas Project in Australia »

McDermott (MDR), with…

MDR

McDermott

$7.28

-0.37 (-4.84%)

GE

General Electric

$6.77

-0.15 (-2.17%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MOH

Molina Healthcare

$135.79

2.32 (1.74%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
Molina Healthcare awarded CHIP contract in Mississippi »

Molina Healthcare…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVEO

Aveo Pharmaceuticals

$2.03

0.01 (0.50%)

, AZN

AstraZeneca

$38.63

0.22 (0.57%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
Aveo Oncology announces immuno-oncology clinical collaboration with AstraZeneca »

AVEO Oncology (AVEO)…

AVEO

Aveo Pharmaceuticals

$2.03

0.01 (0.50%)

AZN

AstraZeneca

$38.63

0.22 (0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GRMN

Garmin

$65.37

0.41 (0.63%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Hot Stocks
Garmin Health, ActiGraph collaborate on wearable solutions for clinical trials »

Garmin International, a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Dec

BIOS

BioScrip

$3.84

0.1 (2.67%)

07:08
12/12/18
12/12
07:08
12/12/18
07:08
Initiation
BioScrip initiated  »

BioScrip initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.